美国完整腹主动脉瘤开窗与标准腔内修复的结局与费用比较
基于Premier医疗数据库2012至2015年17689例择期腔内腹主动脉瘤修复,其中开窗修复1641例(9%)、标准修复16048例(91%)。开窗修复组肾脏和神经系统损伤风险及总费用显著高于标准修复组,死亡率无差异。
要点
- 开窗修复组肾脏损伤(5.8% vs 4.3%)和神经系统损伤(0.7% vs 0.4%)发生率显著高于标准修复组。
- 开窗修复与肾衰竭风险增加相关(OR 1.40,95%CI 1.11-1.76,P=.004),神经系统损伤风险增加(OR 1.91,95%CI 1.02-3.57,P=.04)。
- 开窗修复总费用中位数高于标准修复(28227美元 vs 26781美元,P<.001),校正后平均高1612美元(95%CI 1123-2101美元,P<.001)。
核心结论
- 在择期腔内腹主动脉瘤修复中,与标准腔内修复相比,开窗腔内修复与肾脏和神经系统损伤风险显著增加相关,且校正人口学、合并症和主要并发症后总费用仍显著更高。
研究设计与样本
- 利用Premier医疗数据库(2012-2015年)识别所有择期行标准腔内修复和开窗腔内修复的患者,采用单变量(χ2检验、Student t检验、中位数检验)和多变量(逻辑回归和广义线性模型)分析,校正人口学、合并症和地区特征后检查住院费用和不良结局。
主要发现
- 共17689例择期腔内腹主动脉瘤修复,开窗修复1641例(9%),标准修复16048例(91%)。
- 开窗修复组白人比例更高(86.3% vs 84.3%,P=.03),脑血管病比例更高(8.4% vs 6.7%,P=.01)。
- 开窗修复组总住院时间略长(均值[标准差] 2.40[3.39]天 vs 2.23[3.10]天,P=.03)。
- 开窗修复组任何并发症(11.3% vs 9.6%)、肾脏损伤(5.8% vs 4.3%)和神经系统损伤(0.7% vs 0.4%)发生率显著更高(均P<.05)。
- 两组死亡率(0.8% vs 0.5%)及心脏(4.9% vs 4.4%)、肺部(2.4% vs 2.2%)、肠道(1.5% vs 1.2%)并发症无差异(均P>.05)。
关键数值与推荐
- 多变量逻辑回归:开窗修复与肾衰竭风险增加40%相关(OR 1.40,95%CI 1.11-1.76,P=.004)。
- 多变量逻辑回归:开窗修复与神经系统损伤风险增加91%相关(OR 1.91,95%CI 1.02-3.57,P=.04)。
- 开窗修复总费用中位数显著高于标准修复(28227美元 vs 26781美元,P<.001)。
- 广义线性模型校正后,开窗修复费用平均比标准修复高1612美元(校正费用差1612美元,95%CI 1123-2101美元,P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fenestrated endovascular aneurysm repair (FEVAR) has expanded the indications of this minimally invasive procedure to include patients with pararenal aneurysms. The actual cost of this relatively newer technology compared with standard endovascular aneurysm repair (EVAR) has not been studied before. Thus, the aim of this study was to analyze in-hospital costs and adverse outcomes in patients undergoing FEVAR vs EVAR for intact abdominal aortic aneurysms (AAAs). METHODS: Using the Premier Healthcare Database (2012-2015), we identified all patients who underwent elective EVAR and FEVAR. Univariable (χ2 test, Student t-test, median test) and multivariable (logistic regression and generalized linear modeling) analyses were implemented to examine in-hospital cost and adverse outcomes adjusting for patients' demographics, comorbidities, and regional characteristics. RESULTS: A total of 17,689 elective endovascular AAA repairs were performed; 1641 patients underwent FEVAR (9%), and the remaining 16,048 patients underwent standard EVAR (91%). Patients undergoing FEVAR were more likely to be white (86.3% vs 84.3%; P = .03). Both groups had similar comorbidities except for cerebrovascular disease, which was higher among patients undergoing FEVAR (8.4% vs 6.7%; P = .01). The total length of hospital stay was slightly higher in patients undergoing FEVAR compared with EVAR (mean [standard deviation], 2.40 [3.39] days vs 2.23 [3.10] days; P = .03). The rates of any complication (11.3% vs 9.6%), renal injury (5.8% vs 4.3%), and neurologic injury (0.7% vs 0.4%) were significantly higher in the FEVAR group (all P < .05). No differences were seen in mortality (0.8% vs 0.5%) or cardiac (4.9% vs 4.4%), pulmonary (2.4% vs 2.2%), and bowel (1.5% vs 1.2%) complications between the two groups (all P > .05). In multivariable logistic regression analysis, FEVAR was associated with 40% increased odds of renal failure (odds ratio, 1.40; 95% confidence interval [CI], 1.11-1.76; P = .004) and 91% increased odds of neurologic injury (odds ratio, 1.91; 95% CI, 1.02-3.57; P = .04). The median total cost of the treatment was also significantly higher among patients undergoing FEVAR ($28,227 vs $26,781; P < .001). After adjustment, generalized linear modeling analysis showed that the cost of FEVAR was on average $1612 higher than the cost of EVAR (adjusted cost, $1612; 95% CI, $1123-$2101; P < .001). CONCLUSIONS: In this large cohort of elective endovascular AAA repairs, compared with standard EVAR, FEVAR is associated with significantly increased odds of renal and neurologic injury. In addition, despite adjusting for patients' demographics, comorbidities, and major complications, total cost of FEVAR was significantly higher compared with standard EVAR. This is likely driven by the additional cost of fenestrated endografts and by the increased rate of complications related to FEVAR.
引用
- Locham S, Faateh M, Dhaliwal J, et al. Outcomes and cost of fenestrated versus standard endovascular repair of intact abdominal aortic aneurysm in the United States. J Vasc Surg. 2018. PMID: 30292604. doi:10.1016/j.jvs.2018.06.211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。